Extended-release OAB drug gets FDA OK

August 13, 2007

Overactive bladder can now be treated with an extended-release version of trospium chloride.

Overactive bladder (OAB) can now be treated with an extended-release version of trospium chloride. Sanctura XR, from Indevus Pharmaceuticals, has been approved by the FDA for the once-daily treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride is an anticholinergic compound that blocks the muscarinic receptor, causing relaxation of the detrusor muscle and decreasing bladder contractions. Clinical studies involving 1,300 patients showed the most common side effects of Sanctura XR to be dry mouth and constipation.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.